Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Returning to a normal life via COVID-19 vaccines in the USA: a large-scale agent-based simulation study

View ORCID ProfileJunjiang Li, View ORCID ProfilePhilippe J. Giabbanelli
doi: https://doi.org/10.1101/2021.01.31.21250872
Junjiang Li
1Department of Computer Science & Software Engineering, Miami University, Oxford OH, 45056 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Junjiang Li
Philippe J. Giabbanelli
1Department of Computer Science & Software Engineering, Miami University, Oxford OH, 45056 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Philippe J. Giabbanelli
  • For correspondence: giabbapj@miamioh.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background In 2020, COVID-19 has claimed more than 300,000 deaths in the US alone. While non-pharmaceutical interventions were implemented by federal and state governments in the USA, these efforts have failed to contain the virus. Following the FDA approval of two COVID-19 vaccines, however, the hope for the return to normalcy is renewed. This hope rests on an unprecedented nation-wide vaccine campaign, which faces many logistical challenges and is also contingent on several factors whose values are currently unknown.

Objective We study the effectiveness of a nation-wide vaccine campaign in response to different vaccine efficacies, the willingness of the population to be vaccinated, and the daily vaccine capacity under two different federal plans. To characterize the possible outcomes most accurately, we also account for the interactions between non-pharmaceutical interventions and vaccines, through six scenarios that capture a range of possible impact from non-pharmaceutical interventions.

Methods We use large-scale cloud-based agent-based simulations by implementing the vaccination campaign using Covasim, an open-source ABM for COVID-19 that has been used in several peer-reviewed studies and accounts for individual heterogeneity as well as a multiplicity of contact networks. Several modifications to the parameters and simulation logic were made to better align the model with current evidence. We chose six non-pharmaceutical intervention scenarios and applied the vaccination intervention following both the plan proposed by Operation Warp Speed (former Trump administration) and the plan of one million vaccines per day, proposed by the Biden administration. We accounted for unknowns in vaccine efficacies and levels of population compliance by varying both parameters. For each experiment, the cumulative infection growth is fitted to a logistic growth model, and the carrying capacities and the growth rates are recorded.

Results For both vaccination plans and all non-pharmaceutical intervention scenarios, the presence of the vaccine intervention considerably lowers the total number of infections when life returns to normal, even when the population compliance to vaccines is as low at 20%. We noted an unintended consequence: given the vaccine availability estimates under both federal plans and the focus on vaccinating individuals by age categories, a significant reduction in non-pharmaceutical interventions results in a counterintuitive situation in which higher vaccine compliance then leads to more total infections.

Conclusions Although potent, vaccines alone cannot effectively end the pandemic given the current availability estimates and the adopted vaccination strategy. Non-pharmaceutical interventions need to continue and be enforced to ensure high compliance, so that the rate of immunity established by vaccination outpaces that induced by infections.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The authors thank the Microsoft AI for Health program for supporting this research effort through a philanthropic grant.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study uses secondary data and models, hence it is exempt from IRB or ethics committee approvals.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

This study uses secondary data and models which have been publicly released.

  • Abbreviations

    ABM
    An Agent-Based Model is a computational model that simulates how individuals (i.e., ‘agents’) change through interactions with others and their environment.
    CDC
    The Centers for Disease Control and Prevention is a national public health institute in the United States.
    COVID-19
    Disease caused in humans by a new strain of the severe acute respiratory syndrome coronavirus 2, SARS-CoV-2 (initially named 2019-nCoV).
    VOC-202012/01
    Variant of Concern 2020/12/01 is a new strain, first identified in the UK and currently spreading in the USA, whose unusually large number of changes in genomes result in higher transmissibility.
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted February 03, 2021.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Returning to a normal life via COVID-19 vaccines in the USA: a large-scale agent-based simulation study
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Returning to a normal life via COVID-19 vaccines in the USA: a large-scale agent-based simulation study
    Junjiang Li, Philippe J. Giabbanelli
    medRxiv 2021.01.31.21250872; doi: https://doi.org/10.1101/2021.01.31.21250872
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    Returning to a normal life via COVID-19 vaccines in the USA: a large-scale agent-based simulation study
    Junjiang Li, Philippe J. Giabbanelli
    medRxiv 2021.01.31.21250872; doi: https://doi.org/10.1101/2021.01.31.21250872

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Public and Global Health
    Subject Areas
    All Articles
    • Addiction Medicine (175)
    • Allergy and Immunology (421)
    • Anesthesia (97)
    • Cardiovascular Medicine (901)
    • Dentistry and Oral Medicine (170)
    • Dermatology (102)
    • Emergency Medicine (257)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
    • Epidemiology (8792)
    • Forensic Medicine (4)
    • Gastroenterology (405)
    • Genetic and Genomic Medicine (1864)
    • Geriatric Medicine (179)
    • Health Economics (388)
    • Health Informatics (1292)
    • Health Policy (644)
    • Health Systems and Quality Improvement (492)
    • Hematology (207)
    • HIV/AIDS (395)
    • Infectious Diseases (except HIV/AIDS) (10570)
    • Intensive Care and Critical Care Medicine (564)
    • Medical Education (193)
    • Medical Ethics (52)
    • Nephrology (218)
    • Neurology (1758)
    • Nursing (103)
    • Nutrition (267)
    • Obstetrics and Gynecology (343)
    • Occupational and Environmental Health (461)
    • Oncology (965)
    • Ophthalmology (283)
    • Orthopedics (107)
    • Otolaryngology (177)
    • Pain Medicine (118)
    • Palliative Medicine (43)
    • Pathology (264)
    • Pediatrics (557)
    • Pharmacology and Therapeutics (266)
    • Primary Care Research (220)
    • Psychiatry and Clinical Psychology (1846)
    • Public and Global Health (3989)
    • Radiology and Imaging (655)
    • Rehabilitation Medicine and Physical Therapy (344)
    • Respiratory Medicine (536)
    • Rheumatology (215)
    • Sexual and Reproductive Health (178)
    • Sports Medicine (166)
    • Surgery (197)
    • Toxicology (37)
    • Transplantation (107)
    • Urology (80)